This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
1/26/2023
Good morning, ladies and gentlemen, and welcome to Covalent's Q4 and year-end FY 2022 conference call and webcast. My name is Lara, and I will be your conference operator today. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star then the number one on your telephone keypad. If you would like to withdraw your question, please press star, then the number two. Alternatively, you can submit type questions via the webcast. At this time, I would like to turn the conference over to Mr. Brian Pedler, President and Chief Executive Officer, and Mr. Jason Goral, Interim Chief Financial Officer. Please go ahead, Mr. Pedler and Mr. Goral.
Thanks, Laura. Good morning, fellow investors, and thank you for joining us on this call. Salia Asadzada from Kovalon is helping to coordinate the conference call and webcast today and will now provide us with some instructions.
Thank you, Brian. Good morning, everyone. My name is Salia Asadzada and I am the Executive Assistant to Kovalon's Chief Executive Officer. I would like to thank everyone for taking the time this morning to attend our conference call. We will be discussing the financial statements, MD&A, and press release related to Kovalan's fourth quarter and year-ended September 30, 2022. There will be an opportunity for you to ask questions at the end of our call. Before we begin the discussion, I would like to remind participants that this call and webcast are covered by Kovalan's Safe Harbor Statement. Certain statements included on this conference call may be considered forward-looking. statements involve known and unknown risks uncertainties and other factors that may cause our actual results performance or achievements to be materially different from those implied by our statements and therefore these statements should not be taken as guarantees of future performance or results all forward-looking statements are based on management's current beliefs assumptions and information currently available to us related to to anticipated financial performance, business prospects, partnership opportunities, strategies, regulatory developments, market acceptance, and future commitments, among other things. Participants on this conference call are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Due to risks and uncertainties, including those identified by Kovalon in our public securities filings, Actual events may differ materially from current expectations. Covalent disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. In the management's discussion and analysis, press release, and this call, Covalent has provided non-IFRS measures that are meant to provide further understanding of our results by helping to highlight trends and assist in comparing different periods. The adjusted gross margin and adjusted EBITDA are terms that do not have any standardized meaning and may not be comparable to other companies. These measures are not meant to replace the similar IFRS measures, and any adjusting items may recur in the future. I will now turn the call back over to Brian Pedlar, Covalent's President and Chief Executive Officer.
You're reading a preview of the COV Q4 2022 earnings call.
Free account.
